Enzalutamide
Pfizer,Astellas
['cohort 1', 'brca', 'crpc']
capture cohort 1: mcrpc in 1l tx setting: brca1/2: 13% (somatic: 10%, germline: 3%) brca1/2: rpfs, pfs2, &amp; os (vs hrr non-brca &amp; non-hrrm) outcomes worst for: brca1/2&lt;hrr non-brca&lt;non-brca brca outcomes same whether mono/biallelic or germline/somatic #asco23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @MCG_Urology and @AUB_Lebanon 🇱🇧